GlassScriptPhysician profile
Nilo Elizalde
NPI 1841854635
$3,403.88
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,110 · 2024: $2,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,355 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,355.04 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $515.20 | 2023-2024 | Lybalvi, Aristada, Vivitrol |
| Supernus Pharmaceuticals, INC. | $431.74 | 2024 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $408.11 | 2023-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $314.32 | 2023-2024 | Invega Sustenna, Spravato |
| Abbvie INC. | $313.31 | 2023-2024 | |
| Corium, LLC | $285.18 | 2023-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $276.40 | 2023-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $251.95 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Mycite |
| Teva Pharmaceuticals USA, INC. | $251.93 | 2023-2024 | Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $104.48 | 2024 | Hetlioz, Fanapt |
| Ironshore Pharmaceuticals INC. | $101.58 | 2024 | |
| Lundbeck LLC | $50.47 | 2023-2024 | Rexulti, Brintellix |
| Almatica Pharma LLC | $46.03 | 2024 | Loreev Xr |
| Indivior INC. | $35.05 | 2023 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $18.13 | 2024 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilo Elizalde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.